Adverse Drug Reactions Journal

Select

综述

Rational and safe use of antiepileptics

2006, 8(6): 401-406.

Abstract ( ) PDF ( )

Select

病例报告

Acute hepatitis as result of mizolastine use

2006, 8(6): 406-406.

Abstract ( ) PDF ( )

Select

论著

Clinical study on safety of peginterferon α-2b plus ribavirin for treating chronic hepatitis C

Fan wanhu;．Zhang shuIin

2006, 8(6): 407-410.

Abstract ( ) PDF ( )

Objective:To study the safety of peginterferon α-2b plus ribavirin for treating chronic hepatitis C. Methods:Forty patients with chronic hepatitis C were divided randomizely into two groups:treatment group (26 cases) and control group (14 cases). The two groups were well-matched at entry,with no statistical differences in the patients' characteristics including average age,hight,weight,blood pressure,heart rate,temperature,and so on (P>0.05). The patients in the treatment group were administered with peginterferonα-2b 50 μg subcutaneously,once a week,plus ribavirin 800～1050 mg by mouth,once daily. The patients in the control group were administered with recombinant interferon α-2b 3 MIU subcutaneously,three times a week,plus ribavirin 800～1050 mg by mouth,once daily. The total therapy duration for the two groups was 48 weeks,and a 24-week observation was performed after treatments. Results:The manifestations of adverse reactions in the two groups were almost same,and the common signs and symptoms were fatigue,indisposition,fever,nausea,thrombocytopenia,hypothyroidism,and so on. There was no significant difference between the two groups in the incidence of adverse reactions.Conclusion:The safety of peginterferonα-2b plus ribavirin for treating chronic hepatitis C is comparable to that of recombinant interferonα-2b plus ribavirin.

Select

论著

Clinical studies in effects of osmotic pressure of mixed parenteral nutrition solution on vessel irritation

wang Lina①;wu Yubo①;Zhao Jinpeng②;Guan Yinghui②;Jin Hui①;Jin Mingji①;Yang Hong①

2006, 8(6): 410-414.

Abstract ( ) PDF ( )

Objective:To study the effect of osmotic pressure reduction of mixed parenteral nutrition solution on vessel irritation. Methods:Ninety patients performed with radical operation for advanced gastric carcinoma were divided into 3 groups:peripheral vein administration group,central vein administration group,and routine supplemental solution control group; each group had 30 cases. The patients in the two administration groups were given mixed parenteral nutrition solution and enteral nutrition for 5 days before operation; mixed parenteral nutrition solution on the first day after operation,the enteral nutrition used as an adjunct to mixed parenteral nutrition solution on the third day after operation,and mixed parenteral nutrition solution used as an adjunct to enteral nutrition on the seventh day after operation. The patients in the control group were given routine supplemental solution within one week ofter operation.The content of glucose and amino acid for mixed parenteral nutrition solution in the peripheral vein administration group was < 10% and 3% respectively (osmotic pressure was 900～950 mosm/L). The preparation of mixed parenteral nutrition solution for the central vein administration group was made according to the standard prescription (osmotic pressure was 1200～1300 mosm/L). The nutritive indexes were measured on the day before operation,the third day and the fifth day after operation. The incidence of complications including phlebalgia,extravasation,phlebitis,and superficial phlebothrombosis was observed. Results:The serum transferrin and albumin levels were increased on the seveth days after operation (P<0.01),and the incidence of complications after operation was lower (P=0.024) in the peripheral vein administration group compared with the central vein administration group. There were no statistical differences between the two administration group in their serum transferrin and albumin levels. No severe complications were found in the peripheral vein administration group. Conclusion:The osmotic pressure reduction of mixed parenteral nutritionsolution may decrease the vessel irritation and beneficial to safe drug use.

Select

论著

Study on hemolytic reaction of Xuesaitong injection in vitro

Chen Jinyue①;Qin Yaochun①;Li Haiying①;Wen Jun①;Liang Yu②

2006, 8(6): 414-417.

Abstract ( ) PDF ( )

Objective:To study the effect of Xuesaitong injection on hemolytic degree of human erythrocytes in order to provide evidence for its clinical safe use. Methods:The test solutions were prepared by diluting Xuesaitong injection (containing total saponin of Sanqi 100 mg) to 25 mg/ml,1 6.7 mg/ml,and 10 mg/ml. The hemolytic degree of human erythrocytes caused by the test solutions was measured by spectrometry and routine macroscopy. Results:The hemolytic reaction was caused by the test solutions of 25 mg/ml and 16.7mg/ml,but it was not caused by the test solution of 10 mg/ml. Conclusion:The hemolytic reaction of Xuesaitong injection is related to its concentration. Therefore,Xuesaitong injection should be diluted to appropriate con-centration before administration,and the concentration of solution no more than 10mg/ml is safe.

Select

论著

Study in effects of Dengzhanshengmai capsules on cerebral ischemia and reperfusion injury in rats

Wu You;Jia Jianping

2006, 8(6): 417-422.

Abstract ( ) PDF ( )

Objective:To observe the effect of Dengzhanshengmai capsules on cerebral ischemia and reperfusion injury in rats,and discuss its mechanism. Methods:Eighty rats were divided into 5 groups:sham-operated group 1,sham-operated group 2,saline control group,low-dose Dengzhanshengmai group,and high-dose Dengzhanshengmai group. Each group had 16 rats. The middle cerebral artery occlusion model in rats were made by the modified suture-occluded method of Zea longa. The rats were administrastion with Dengzhanshengmai capsules orally before and after cerebral ischemia. Neurological score was carried out. Some haematological indexes (such as prothrombin time,fibrin content,and maximum agglutination rate of platelets),plasma endothelin level,and serum nitrogen oxide level were measured. The size of crebral infarct and edema,the activity of SOD,and the content of MDA were measured as well. Results:The neurological score in the low-dose and high-dose Dengzhanshengmai groups after 2 and 24 hours reperfusion was lower than those of the control group(1.75±0.68?1.71±0.77 vs2.35±0.86,1.88±0.81、 1.71±0.69 vs2.65±1.17,P<0.05). The PT in the high-dose Dengzhanshengmai group was longer than that of the saline control group (18.0±0.8s vs17.0±0.6s,P<0.05) while the level of ET was lower(13.9±4.9 pg/ml vs26.3±13.2,P<0.05). The infarct size and edema size in the Dengzhanshengmai group were smaller than those of the saline control group(10.3±3.8%? 9.7±5.7% vs11.9±3.0%,7.7±3.0%、 6.9±3.9% vs 18.3±7.0%,P<0.05),The activity of SOD in the Dengzhanshengmai group was higher than that of the saline control group (291±78 U/mg、 301±92U/mg vs213±40 U/mg,P<0.05)while the content of MDA was much lower(1.41±0.47nmol/mg、 1.36±0.61nmol/mg vs 2.09±0.32 nmol/mg,P<0.05,P<0.01). But no significant differences were found in the levels of Fg,maximum aggregation of platelets,and nitrogen oxide. Conclusion:Dengzhanshengmai capsules is effective for preventing and treating cerebral ischemia and reperfusion injury.The mechanisms of its effect may be associated with improving the activities of antioxidases,suppressing lipidperoxidation,alleviatingthe injuries induced by free radicals,suppressing blood agglomeration,and reducing blood vessel resistance.

Select

病例报告

Anaphylactic shock induced by iopromide

2006, 8(6): 422-422.

Abstract ( ) PDF ( )

Select

调查研究

Clinical analysis of selective serotonin reuptake inhibitor discontinuation syndrome in 42 patients

Huang Jiwei;Peng Haiying

2006, 8(6): 423-425.

Abstract ( ) PDF ( )

Objective:To discuss the clinical features,predisposing factors,and prevention of SSRI discontinuation syndrome. Methods:The clinical features,the predisposing causes,and management in 42 patients with SSRI discontinuation syndrome were investigated retrospectively. Results:The main symptoms of SSRI discontinuation syndrome were dizziness,nausea,vomiting,headache,abnormal sensation,depressed mood,insomnia,anxiety,and agitation. The symptoms began within 1 to 5 days after discontinuation of SSRI and persisted 1 to 7 days. Of the 42 patients,27 had taking paroxetine,6 sertraline,6 citalopram,and 3 fluoxetine. The predisposing factors of SSRI discontinuation syndrome were sudden withdrawal by oneself (30 cases),missed doses (6 cases),dose reduction (4 cases),and drug switching (2 cases). Conclusion:There should be care of discontinuation syndrome after abrupt cessation of SSRI in clinical practice. The SSRI implicated most often is paroxetine. The gradual tapering or use of an agent with longer half-life is necessary in order to avoid the development of SSRIdiscontinuation syndrome.

Select

调查研究

Clinical analysis of causes of misdiagnosis to Guanxinsuhe pills-related renal injury in 9 cases

Song Yan;Zhang Yiyan;Li Jijun;Zhang Liwei;Yao Fenghua;Yin Pei;Chen Fengqun;Li Xueyi

2006, 8(6): 425-428.

Abstract ( ) PDF ( )

Objective:To analyse the causes of misdiagnosis to Guanxinsuhe pills-related renal injury in order to be benefial to its exact diagnosis and treatment. Methods:Thirty-one cases with Guanxinsuhe pills-related injury were reviewed,and the causes of misdiagnosis to 9 of them were analysed. Results:All of the 9 cases were middle-aged and elderly patients. They were diagnosed as chronic tubulointerstitial nephrothy with renal tubular acidosis,renal glucoseuria,hyposthenuria,and decreased renal function in varying degree. The severity of anemia was not parallel to decreased renal function. Of the 9 patients,7 took Guanxinsuhe pills according to the dosage of pharmacopoeia,and 2 took the dosage higher than that of pharmacopoeia. Of the cases,5 were misdiagnosed as hypertensive nephropathy,2 diabetic nephropathy,and 2 chronic glomerulonephritis. Seven of the 9 patients were not asked about the history of Guanxinsuhe pills use,and 2 patients had the history of Guanxinsuhe pills use but they were not diagnosed as Guanxinsuhe pills-related renal injury. Conclusion:The most of cases with Guanxinsuhe pills-related renal injury are middle-aged and elderly patients. Since clinician are not well aware of renal toxicity and renal injury of Guanxinsuhe pills,the Guanxinsuhe pills-related renal injury of middle-aged and elderly patients with diabetic or hypertension are usually misdiagnosed as diabetic nephropathy or hypertensive nephropathy. Therefore,the patients with renal injury,especially in middle-aged and elderly patients,should be asked about the history of Guanxinsuhe pills use in order to avoid the missed diagnosis or misdiagnosis.

Select

调查研究

Effects of etimicin plus other antibacterials on renal function in elderly patients with severe pneumonia

Li Yalin;Zhao Yan;Tang Hui;Li Xiaoyu;Sun Changyi;Qin Jian

2006, 8(6): 428-430.

Abstract ( ) PDF ( )

Objective:To investigate the effects of etimicin plus other antibacterials on renal function in elderly patients with severe pneumonia. Methods:Forty-seven elderly patients with severe pneumonia who were receiving etimicin plus other antibacterials were analysed retrospectively. Of the 47 elderly patients,32 were 60～79 years old,15 were old than 80 years. The changes in serum creatinine (Scr),blood urea nitrogen (BUN),and urine protein were observed before and after treatment,and creatinime clearance rate (Ccr) were calculated. Results:Before etimicin treatment,the mean value of Scr,BUN and Ccr in the 42 patients were 106±26.5 μmol/L,6.3±2.9 mmol/L,and 44±14 ml/min respectively. After etimicin treatment,the mean value of Scr and BUN were reduced to 97±17.7 μmol/L and 5.4±2.6 mmol/L,respectively,and Ccr was elevated to 46±13 ml/min. But there were no statistical differences between before treatment and after treatment in their data (P>0.05). Urine protein was decreased obviously after treatment (P<0.01). Conclusion:There is no marked renal toxicity of etimicin plus other antibacterials in the treatment of the elderly patients with severe pneumonia,so it might be a safer therapy for thepatients.

Select

安全用药

Adverse reactions to bevacizumab and its combination with chemotherapy regimen

2006, 8(6): 431-433.

Abstract ( ) PDF ( )

Select

安全用药

Bacillus Calmette-Guérin lymphadenitis:Clinical presentation,predispoding factors,prevention,and management

2006, 8(6): 433-436.

Abstract ( ) PDF ( )

Select

中药不良反应